Austria: Schoenherr advises Neuraxpharm on the acquisition of Easypharm

11 March 2020 | general

Schoenherr advised Neuraxpharm, a portfolio company of Apax partners, on the acquisition of Austrian consumer healthcare company Easypharm OTC GmbH. The deal was closed on 20 January 2020.

"We are proud to have successfully advised on this important transaction in the pharma sector," said Schoenherr partner and co-head of the corporate/m&a practice group Sascha Hödl. "Our legal advice helped Neuraxpharm strengthen its position on the Austrian market."

Neuraxpharm Group (Neuraxpharm) is a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders. With the acquisition of Easypharm, the company further consolidates its expansion into the Austrian market.

Easypharm is a pharmaceutical company headquartered in Gießhübl, near Vienna. The company focuses on consumer healthcare mainly via its two leading CNS brands, easysleep® and easyrelax®.

The Schoenherr team was led by Sascha Hödl (partner), Maximilian Lang (counsel), Teresa Waidmann (attorney at law) and Leon Scheicher (associate).

Easypharm was represented by Hochedlinger Luschin Marenzi Kapsch Rechtsanwälte GmbH.